No statistically significant correlation was observed between bevacizumab clearance and tumor location (gastroesophageal junction versus stomach), type of gastric cancer (diffuse, intestinal, or mixed), baseline plasma VEGF-A, baseline lactate dehydrogenase, liver metastases, HER2 status, or gender. This evidence concerns the gene ERBB2 and gastric cancer.